MX420767B - Proteina de union al factor h modificada - Google Patents

Proteina de union al factor h modificada

Info

Publication number
MX420767B
MX420767B MX2019002248A MX2019002248A MX420767B MX 420767 B MX420767 B MX 420767B MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 420767 B MX420767 B MX 420767B
Authority
MX
Mexico
Prior art keywords
binding protein
modified factor
fhbp
modified
factor
Prior art date
Application number
MX2019002248A
Other languages
English (en)
Spanish (es)
Other versions
MX2019002248A (es
Inventor
Tang Christoph M
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2019002248A publication Critical patent/MX2019002248A/es
Publication of MX420767B publication Critical patent/MX420767B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2019002248A 2016-08-31 2017-08-31 Proteina de union al factor h modificada MX420767B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (2)

Publication Number Publication Date
MX2019002248A MX2019002248A (es) 2019-09-18
MX420767B true MX420767B (es) 2025-02-10

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002248A MX420767B (es) 2016-08-31 2017-08-31 Proteina de union al factor h modificada

Country Status (13)

Country Link
US (1) US12497432B2 (enExample)
EP (1) EP3506934A1 (enExample)
JP (1) JP7525093B2 (enExample)
KR (1) KR102643280B1 (enExample)
CN (1) CN109890412B (enExample)
AU (1) AU2017319218B2 (enExample)
BR (1) BR112019003957A2 (enExample)
CA (1) CA3035159A1 (enExample)
GB (2) GB201614687D0 (enExample)
IL (1) IL265078B2 (enExample)
MX (1) MX420767B (enExample)
WO (1) WO2018042178A1 (enExample)
ZA (1) ZA201901862B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
CN116323680A (zh) * 2020-09-29 2023-06-23 出光兴产株式会社 肽标签和包含其的附加有标签的蛋白
IN202321021121A (enExample) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
NZ562998A (en) * 2002-10-11 2008-05-30 Novartis Vaccines & Diagnostic Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053091A2 (en) * 2002-12-10 2004-06-24 Lorantis Ltd. STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
PT2172213E (pt) * 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
WO2006011060A2 (en) * 2004-07-23 2006-02-02 Chiron Srl Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
EP2682126B1 (en) * 2005-01-27 2016-11-23 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
WO2009104097A2 (en) * 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
ES2557282T3 (es) * 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
RU2477145C2 (ru) * 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
WO2009150531A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
WO2010028096A2 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
CN104548082A (zh) * 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
CA2759400A1 (en) * 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
EP2470204B1 (en) * 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CN102869378A (zh) * 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
EP4036104B1 (en) * 2010-03-30 2024-02-21 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
EP2556085A2 (en) * 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
EP2585106A1 (en) * 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
MY166172A (en) * 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
JP2015505309A (ja) * 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
US10598666B2 (en) * 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
CA2960030C (en) * 2012-03-09 2020-02-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR112014031386A2 (pt) * 2012-06-14 2017-08-01 Pasteur Institut vacinas para meningococos do sorogrupo x
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
EP2964665B1 (en) * 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
AU2014316722B2 (en) * 2013-09-08 2017-09-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EA034954B1 (ru) * 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EP3172224B1 (en) * 2014-07-23 2022-06-29 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
US20170326220A1 (en) 2014-11-28 2017-11-16 Janssen Vaccines & Prevention B.V. Meningitis b vaccine
KR20170103009A (ko) * 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
JP7010961B2 (ja) * 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法

Also Published As

Publication number Publication date
BR112019003957A2 (pt) 2019-06-25
CN109890412A (zh) 2019-06-14
US12497432B2 (en) 2025-12-16
ZA201901862B (en) 2020-09-30
GB201614687D0 (en) 2016-10-12
IL265078A (enExample) 2019-04-30
IL265078B1 (en) 2023-04-01
EP3506934A1 (en) 2019-07-10
AU2017319218A2 (en) 2019-05-02
NZ751995A (en) 2024-03-22
KR20190064577A (ko) 2019-06-10
CA3035159A1 (en) 2018-03-08
IL265078B2 (en) 2023-08-01
CN109890412B (zh) 2025-04-04
GB2568440B (en) 2022-08-17
GB2568440A (en) 2019-05-15
AU2017319218B2 (en) 2021-10-28
KR102643280B1 (ko) 2024-03-05
WO2018042178A1 (en) 2018-03-08
JP2019526261A (ja) 2019-09-19
US20220112249A1 (en) 2022-04-14
MX2019002248A (es) 2019-09-18
JP7525093B2 (ja) 2024-07-30
AU2017319218A1 (en) 2019-04-18
GB201903866D0 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
PH12020550051A1 (en) Glp-1 compositions and uses thereof
DOP2019000117A (es) Nuevos derivados de quinolina
BR112018071678A2 (pt) compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv
MX2023003875A (es) Formulacion de una vacuna peptidica.
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX420767B (es) Proteina de union al factor h modificada
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
MX364942B (es) Peptidos antimicrobianos.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12017500450A1 (en) Flavivirus virus like particle
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MX2020008125A (es) Composiciones que comprenden berberina.
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX381255B (es) Vacunas contra el reovirus aviar.
EA201890209A1 (ru) Композиция, содержащая танины
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c